Status
Not open for further replies.

rcharlton

Moderator emeritus
Joined
Jun 20, 2005
Messages
610
Reason
PALS
Diagnosis
11/2005
Country
CA
State
Ontario
City
Toronto
Check this out. I love studies like this that suggest a natural product readily available in organic form at a reasonable cost may have significant therapeutic benefit for PALS!

Here is the abstract:

The effect of epigallocatechin gallate on suppressing disease
progression of ALS model mice


Epigallocatechin gallate(EGCG)is a constituent of green tea, and increasing evidence suggests thatEGCGhas neuroprotective effects on oxidative stress-injured neuronal cells, especially motoneurons. Although the neuroprotective effects of EGCG have been demonstrated in Parkinson’s and Alzheimer’s diseases and ischemic stroke models, there has been no report on the effect ofEGCGon an in vivo model of amyotrophic lateral sclerosis (ALS). This study was undertaken to evaluate the effect of EGCG on ALS model mice with the human G93A mutated Cu/Zn-superoxide dismutase (SOD1) gene. We treated each group of 11 ALS model mice with EGCG (1.5, 2.9, and 5.8g/g body weight), dissolved in 0.5 ml of 0.9% sterile NaCl, and one group of 11 with 0.5 ml of 0.9% sterile NaCl (control group) intraorally every day after 60 days of age (presymptomatic treatment).

The treatment of more than 2.9g EGCG/g body weight significantly prolonged the symptom onset and life span, preserved more survival signals, and attenuated death signals. These data suggest that EGCG could be a potential therapeutic candidate for ALS as a disease-modifying agent.

© 2005 Elsevier Ireland Ltd. All rights reserved.

Authors:

Seong-Ho Koh a,1, Sang Mok Lee a,1, Hyun Young Kima, Kyu-Yong Lee
a, Young Joo Lee a, Hee-Tae Kima, Juhan Kima, Myung-Ho Kima, Myung Sil Hwang b, Chiwon Songb, Ki-Wha Yang b, Kwang Woo Lee c, Seung Hyun Kima,∗, Ok-Hee Kimb

a Department of Neurology, Institute of Biomedical Science, College of Medicine, Hanyang University, #17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea

b Department of Toxicological Research, National Institute of Toxicological Research, KFDA, Seoul, Republic of Korea

c Department of Neurology, Neuroscience Center, Seoul National University, Seoul, Republic of Korea

Received 31 August 2005; received in revised form 10 October 2005; accepted 25 October 2005
 
Status
Not open for further replies.
Top